Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
JEMPERLI▼ Video Library
Spotlight: Shining a Light on Patient Care in Endometrial Cancer (EC).
Highlights from a virtual peer-to-peer meeting reviewing RUBY clinical trial results and the safety and efficacy of dostarlimab plus chemotherapy in mismatch repair proficient (MMRp)/no specific molecular profile (NSMP) EC case studies.
Jemperli (dostarlimab) | Prescribing information
Dr Ainhoa Madariaga
Case study: Dostarlimab in combination with chemotherapy in a patient with MMRp NSMP EC
Prof. Domenica Lorusso
RUBY: Dostarlimab in combination with chemotherapy in
advanced/recurrent EC
Dr Adelheid Seebacher
Case study: Management of immune-related adverse reactions
in MMRp EC
POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.
PM-IE-DST-WCNT-250008 | Date of Preparation: March 2026
Expert Thoughts with Dr Ana Oaknin
Jemperli ▼ (dostarlimab) | Prescribing information
The Importance of Biomarkers
in Endometrial Cancer
Understanding
The RUBY Trial Results
POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.
PM-IE-DST-WCNT-250009 | May 2026
How Can JEMPERLI Help Your Next Appropriate Patient?
For healthcare professionals registered in the Republic of Ireland only
We have created some resources to help you support your patients who have been prescribed JEMPERLI
JEMPERLI Indication
- JEMPERLI is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.
- JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.
© GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
PM-IE-DST-WCNT-250004 | May 2026
